Competitive Molecule Notes

DAPAGLIFLOZIN

The next dapagliflozin share shift will be won where the care plan breaks

FOR LEADERS DEFENDING DEFAULT STATUS, CHALLENGERS DISPLACING HABIT, AND SELECTIVE-SHARE BRANDS CAPTURING A NEGLECTED CLINIC WORKFLOW.



Integrated molecule playbook



Molecule-wide Circulation

YOUR POSITION	THE COMPETITIVE JOB
LEADER Defend default	Turn prescription leadership into the clinic's dependable routine for safety, follow-up and continuity.
CHALLENGER Displace habit	Make the comparison about completed clinical reviews and resolved friction after the molecule decision.
SELECTIVE SHARE Capture one wedge	Concentrate on one clinic segment where initiation, handover or refill continuity repeatedly fails.

DAPAGLIFLOZIN

This note is shared with leadership teams of major competing dapagliflozin brands in India. Direct competitors are being shown the same opportunity.

A glucose reminder cannot hold together a diabetes, heart-failure and kidney-care franchise.

The territory is prescription-to-reviewed-plan continuity across specialties. The clinic retains control of care. A brand earns preference by making the chosen care plan easier to complete.



STRATEGIC CHOICE

OWN THE HANDOVER TO THE NEXT CLINICAL DECISION

Dapagliflozin can enter a patient's life through diabetes care, heart failure or CKD. The commercial gap opens when nobody connects the reason for treatment, the safety plan, the next review and the actual pack being used. The first-principles opportunity is to make that connection a repeatable clinic routine.

CONVENTIONAL BRAND ACTIVITY	MOLECULE-WIDE CLINIC WORKFLOW
Repeat glucose and organ-protection claims	Record why this clinician selected dapagliflozin for this patient and who owns follow-up.
Send every patient the same reminder	Use one shared continuity record with only the condition modules the clinician selects.
Measure messages delivered or packs moved	Measure whether the next due review ended in a documented clinical plan.
Treat all discontinuation as lost business	Separate unreviewed dropout from appropriate interruption, switching and patient choice.
Add another campaign to the rep call	Give the clinic a practical way to close a missed review, private concern or supply discrepancy.

THE STRATEGIC CHOICE

Make the completed handover and review the unit of competition. The service earns its place only if it reduces unfinished work for the clinic. Adherence, test completion and refills contribute to that review; none is an adequate substitute for it.

This architecture is molecule-wide because the clinical tasks recur across competing brands. It remains indication-specific because a person with HF without diabetes does not need the same prompts as a person receiving a glucose-lowering combination.

The competitor to beat is the team whose support becomes useful enough for the clinic to keep using.

CATEGORY PROVOCATION

THE EVIDENCE EXPANDED BEFORE THE BRAND ROUTINE DID

Dapagliflozin is no longer understood adequately through a single HbA1c story. Its evidence spans selected T2D, HF and CKD populations. The resulting opportunity is broader continuity of care after clinician selection, with claims bounded by the actual population, endpoint and Indian product label.

CONTEXT	SCIENTIFIC BASIS	IMPLICATION FOR THE CLINIC
Type 2 diabetes	ADA 2026 and the October 2026 ADA/EASD consensus place organ outcomes alongside glucose goals in appropriate patients. [8,9,13]	Explain the selected purpose; normal glucose does not settle the full treatment question.
HFrEF	DAPA-HF reduced the composite of worsening HF or cardiovascular death versus placebo on background care.	Connect the prescription to the HF team's follow-up, symptoms and volume plan.
HF with EF above 40%	DELIVER reduced worsening HF or cardiovascular death as a composite endpoint. [26]	HF support cannot be confined to reduced-EF or diabetic patients.
CKD at risk of progression	DAPA-CKD reduced its kidney/CV composite in selected albuminuric CKD, with and without T2D.	Arrange the clinician's renal review and prevent confusion between glucose response and kidney purpose.

WHERE THE BRAND BECOMES VULNERABLE

The patient hears "sugar tablet"; the cardiologist is treating HF. The pharmacist supplies a different formulation; the clinic never sees it. A renal report or private genital symptom triggers silent non-use. These are plausible points of failure to investigate, not measured national dropout rates.

Product recall wins attention. A completed care plan can earn a place in the clinic's working day.

Do not claim universal mortality benefit, CKD reversal, weight-loss treatment, superiority to another SGLT2 inhibitor, or identical outcomes for every combination. Trial evidence does not prove the proposed service improves outcomes.

INDIA MARKET EVIDENCE

THE CROWD IS REAL AND THE DENOMINATORS MATTER

Public sources establish a substantial, fragmented competitive field. They do not establish an auditable October 2026 national dapagliflozin market value, prescription prevalence, specialty split or complete brand ranking. The latest reliable public observations located are presented with their original dates.

PUBLIC EVIDENCE	VERIFIED OBSERVATION	LIMIT ON USE
Competition [1]	AstraZeneca's FY25 report cites 350+ generic brands of dapagliflozin and combinations in IQVIA MAT December 2024.	Includes combinations. Not today's count of monotherapy brands or active companies.
Value proxy [2]	NPPA's May 2025-data worksheet lists total MAT of INR417.75 crore for its dapagliflozin 10 mg dataset.	The sheet excludes AstraZeneca, Sun and Abbott Healthcare from price fixation and leaves their MAT cells blank. This is an incomplete covered universe, not total molecule sales.
Leader signal [1]	The FY25 report describes Forxiga as the No. 1 dapagliflozin brand by value and cites 120+ monotherapy brands.	Company-reported, dated position; not independent verification of current national rank.
Challenger signal [3]	Eris's FY25 report places Gluxit fourth among generics in its disclosed market context.	A branded-generic subset position, not fourth across every dapagliflozin formulation.
Prescription proxy [4]	One Kochi nephrology cohort: 81/399 eligible patients received an SGLT2 inhibitor in 2024; 79 received dapagliflozin.	Local cohort: 20.3% SGLT2 use and 19.8% dapagliflozin use, calculated. Neither is national prescription prevalence.

The count and value sources cover different universes. Do not add them, average them, infer market shares from them or use the NPPA denominator to demote an excluded innovator. A crowded market also does not imply equal shares.

The evidence supports competitive pressure. It does not license a fabricated leaderboard.

MAT means moving annual total. The 2026 NPPA file uses May 2025 data; publication year is not the sales period. The original total is INR 4,177,480,046, divided by 10 million to express crore. No current national growth rate is inferred.



COMPETITIVE MAP AND PRESCRIBERS

CHOOSE THE COMPETITIVE ARENA BEFORE ASSIGNING THE POSTURE

A team may lead in one formulation, channel or geography and challenge in another. Define the market before choosing defend, attack or selective capture. Plain dapagliflozin and glucose-lowering fixed-dose combinations are not interchangeable commercial or clinical universes.


ILLUSTRATIVE FRANCHISES	PUBLIC BASIS AND INTERPRETATION
Forxiga / AstraZeneca; Oxra / Sun; Lveffect / Abbott Healthcare	Listed in the NPPA sheet, with special exclusion noted. Presence does not establish current availability or comparable audited shares. [2]
Udapa / USV; Dapavel / Intas; Dapanorm / Alkem	Named 10 mg entries in the same dated dataset. Illustrative competitors, not an assigned national rank. [2]
Gluxit / Eris; Glucreta / Torrent; Dapaglyn / Zydus	Further named entries, illustrating fragmentation across established marketers. [2,3]

PRESCRIBER SEGMENT	HIGHEST-VALUE WORKFLOW TO TEST
Diabetologists and endocrinologists	Purpose, combination reconciliation, glucose review and hypoglycaemia-risk context.
Physicians and general practitioners	Longitudinal continuity, affordability, repeat prescriptions and specialist handover.
Cardiologists and HF teams	Post-discharge ownership, volume/diuretic context and prompt clinical reassessment.
Nephrologists	Label-appropriate selection, eGFR/UACR interpretation and shared-care closure.

These are clinically meaningful prescriber priorities, not a verified national specialty ranking. Obtain a current licensed IQVIA, PharmaTrac, AWACS or equivalent audit before quoting market leadership or allocating resources by prescription share.

Audit request: MAT and recent quarters; new/repeat prescriptions; value and standardised units; specialty; geography; plain versus each FDC; strengths, pack sizes and mother-brand rules; marketer ownership; channel coverage and exclusions. Require the same definition for every competitor.





EMBEDDED CLINICAL ENGINE

RESPONSIBLE USE IS THE ENTRY CONDITION

The service starts after the treating clinician has diagnosed the condition, assessed suitability and chosen dapagliflozin. Routine enrolment is for consenting adults with a named clinic, an agreed contact channel and an accessible route to urgent care.

NON-NEGOTIABLE	WHAT THE CLINIC MUST ESTABLISH
Indication and product fit	Selected T2D, HF and/or CKD purpose; exact product and formulation; current approved Indian PI mapped by medical review. [5–7]
Baseline clinical assessment	Relevant renal function, volume status, comorbidities and concomitant medicines reviewed by the clinician. [14,17,18]
Purpose and practical understanding	The patient can explain the clinician's purpose and how to seek help, without being promised every trial benefit.
Safety route	Private symptom reporting, urgent-care instructions and a named person responsible for clinical handoff.
Illness and procedure plan	Individual clinician-issued instructions exist; the service can connect the patient back to their clinical team. [12]
Review closure	The due date, reviewer and ordered information are recorded. Completion requires a documented clinician disposition.

The patient service never diagnoses, recommends dapagliflozin, chooses a dose, or tells a patient to start, stop, switch or restart treatment.

The routine pilot excludes paediatric use, pregnancy/breastfeeding, suspected type 1 diabetes or marked insulin deficiency, dialysis, transplantation and unstable acute illness. Such cases require individual specialist assessment and the applicable product label. Exclusion from this service is not a declaration that every use is contraindicated.

A clinically appropriate discontinuation, switch or referral is successful care. Staff must never suppress it to preserve retention figures. Eligibility cannot be inferred by a chatbot from glucose, eGFR, a symptom answer or a pharmacy purchase.

This is a service architecture for clinician-selected treatment, not a prescribing protocol. The clinic remains accountable for clinical assessment and treatment decisions.

LABEL AND EVIDENCE BOUNDARIES



A BROAD EVIDENCE BASE DOES NOT CREATE A UNIVERSAL LABEL

Medical approval must reconcile guideline recommendations with the current Indian authorisation for the exact brand, strength and combination. Public sources establish the direction of travel; they cannot certify every competitor's current label.

ISSUE	VERIFIED DISTINCTION	OPERATING RULE
CKD eligibility	AstraZeneca's November 2022 India disclosure describes initiation at eGFR ⩾25 in CKD, including without diabetes. KDIGO's class guidance includes ⩾20 in specified populations. [5,14]	Do not convert a guideline threshold into blanket Indian-brand permission. Verify initiation and continuation separately.
HF indication	AstraZeneca's July 2023 India disclosure extends adult HF use across ejection fractions. [6]	A non-diabetic HF module is defensible only for the chosen product's approved indication and clinician-selected patient.
Glucose effect	The current UK SmPC describes reduced glucose-lowering efficacy below eGFR 45. [18]	Separate glycaemic response from the selected cardiorenal purpose; clinician reviews further glucose treatment.
Combination transfer	Torrent's STALIX DM PI states an adult T2D indication for its dapagliflozin/sitagliptin/metformin FDC. [7]	Component-level HF/CKD discussion does not establish an HF/CKD indication for the FDC.
International safety update	FDA June 2026 labelling updates genitourinary warnings, including serious infection in people without diabetes. [17]	Use it to inform medical review; it is not Indian marketing authorisation.



No automatic dose escalation for "stronger organ protection". A plain-tablet strength, a twice-daily combination and an extended-release combination require separate prescription reconciliation. The service stores the clinician's plan without deriving a regimen.

eGFR units: mL/min/1.73 m². KDIGO 2024 remains the published CKD guideline; the 2027 focused update is a public-review draft as checked on 17 October 2026 and is not adopted here. [23] The latest approved Indian PI is a deployment gate.

CENTRAL COMMERCIAL AND BEHAVIOURAL DRIFT

THE CENTRAL LEAKAGE IS AN UNRESOLVED CARE PLAN

Brand loss often becomes visible at refill. The cause may have appeared much earlier: an unclear purpose, an embarrassing symptom, a missed review, another specialist's instruction or a pack discrepancy. These mechanisms should be measured locally before they are used to size an opportunity.

WHERE THE PLAN DRIFTS	PATIENT OR CLINIC FRICTION	COMMERCIAL CONSEQUENCE TO TEST
Purpose becomes "sugar only"	Normal glucose undermines confidence in an HF/CKD prescription.	Unexplained non-use before a refill.
Early concern stays private	Genital symptoms, dizziness or poor intake are not discussed.	Loss of trust attributed to the medicine.
Fluid advice conflicts	Generic hydration messages contradict an HF plan.	The enabling service becomes a liability.
A report has no reviewer	A renal result arrives without interpretation or follow-up.	Unsupervised change or avoidance of care.
Specialty handover disappears	Each team assumes another owns the next decision.	The multi-indication franchise fragments.
Interruption has no return path	A procedure or illness leaves treatment status unclear.	A temporary plan becomes an indefinite lapse.
Supply and prescription diverge	Affordability, stock or formulation substitution goes unseen.	The intended prescription is not fulfilled.

DEFINE LEAKAGE HONESTLY

Avoidable leakage means an unresolved care or access task that the clinic could reasonably have closed. A clinician-directed change, a suitable lower-cost alternative, withdrawal of consent or informed patient refusal is not commercial failure by definition.

Earn continuity by resolving the reason for the gap. Pressure to retain the pack destroys the premise.

The leakage model is a strategic hypothesis. No India-wide dropout, substitution or preventable-discontinuation percentage is asserted.

Competitive Molecule Notes

MOMENTS THAT MATTER

NINE MOMENTS CONNECT THE PRESCRIPTION TO A REVIEWED PLAN



Each moment has a clinic task and an observable end point. Patient support stays neutral; brand preference is earned in the professional relationship.

MOMENT	CLINIC TASK	PATIENT RISK OR FRICTION	BRAND OPPORTUNITY
1 Selection handover	Record purpose, exact prescription and review owner.	Several specialists; unclear reason for use.	Support the clinician's chosen plan.
2 First pack	Confirm access and understanding.	Cost, stock or unexpected formulation.	Reduce fulfilment friction.
3 Early safety check	Route intake, volume and private symptom concerns.	Dizziness or genital symptoms remain unreported.	Earn confidence through reachable care.
4 Illness or procedure	Connect to the clinician's individual plan.	Vomiting, fasting, surgery or acute illness.	Make safe handoff dependable.
5 Weeks 2–4	Complete the planned clinical review.	Contact occurs without a clinical decision.	Compete on closure of early uncertainty.
6 Condition follow-up	Review ordered glucose, renal or HF information.	Wrong test, missed test or no interpretation.	Support the relevant specialty pathway.
7 Refill	Reconcile prescription intent, access and supply.	Missed doses or unnoticed substitution.	Protect authorised continuity.
8 Partial response	Review actual use, goals and whole regimen.	"It did not work"; duplicate tablets.	Enable disciplined reassessment.
9 Re-entry or transfer	Close the lapse or specialist handover.	Old instructions remain in circulation.	Sustain a useful clinic relationship.

Cadence is a service design adjusted by the clinician. Urgent symptoms bypass it. A 2–4 week checkpoint neither mandates universal renal testing nor replaces earlier HF post-discharge follow-up. [10–12,14–19]

INTEGRATED CLINIC SERVICE

CARDIO RENAL METABOLIC CONTINUITY

The generic service architecture is the clinic-branded Cardio Renal Metabolic Continuity pathway. Its patient-facing name can be “My Clinic Care Continuity”. Neither name contains a product brand or promises disease control.

LAYER	WHAT IT DOES	ACCOUNTABLE OWNER
One shared care record	Keeps the clinical purpose, current clinician plan, selected modules, next review and handover status together.	Treating clinic; one named review owner.
Core continuity spine	Consent, access, teach-back, private concerns, due review, refill friction and re-entry.	Clinic coordinator with trained backup.
Optional condition modules	T2D glucose review, HF follow-up or CKD follow-up only when selected. A patient can have more than one.	Relevant clinician with one coordinating owner.
HCP support layer	Evidence, label checks, case learning, review aids and service performance. Brand may appear after molecule selection.	Medical governance and trained field team.
Commercial learning layer	Aggregate clinic adoption and independent, defined-market commercial movement.	Analytics with separated access.

LOW FRICTION IS PART OF THE STRATEGY

The clinician selects the modules and dates. The coordinator confirms access and understanding, collects only necessary information and prepares a concise review queue. The clinician reviews the issue and records a disposition. The coordinator confirms that the patient received the plan and books the next step.

Use the clinic’s existing phone, secure message channel and appointment process where possible. A paper-assisted route must remain available. A smartphone app, daily logging and patient self-diagnosis are not entry requirements.

One accountable reviewer matters more than another dashboard.

Service identity and clinical records belong to the clinic. Transparent sponsorship disclosure, where required, must not become patient-facing product promotion or preferential access to care.

MODULES AND CADENCE

BUILD A RELIABLE NEXT STEP INTO EVERY CONTACT

This is an illustrative operating cadence, not a universal medical schedule. The clinician can shorten or extend intervals, select fewer modules or use the existing visit plan. Every contact should finish a task or trigger a defined handoff.

WHEN	MODULE AND ACTION	EVIDENCE OF COMPLETION
Day 0	Record consent, selected indication/module, prescription, clinic contacts and next review. Clinic provides purpose and safety education.	Named owner and due date; patient teach-back recorded.
Days 2–3	Confirm the first supply was accessible and instructions understood. Escalate cost, pack or use discrepancies.	Access confirmed or clinic action assigned.
Days 7–10	Private tolerability and access check; capture symptoms, reduced intake or difficulty following the clinician's plan.	Concern routed and acknowledged; no automated reassurance.
Weeks 2–4	Clinic review of actual use, concerns and any ordered information. Update the authorised plan.	Documented clinical disposition and next date.
Around 3 months in T2D	Arrange the clinician-ordered glycaemic review after treatment change or if goals are unmet. [11]	Results interpreted, not simply uploaded.
Condition-specific dates	Renal/UACR review or HF symptom/volume review only as ordered.	Selected module has an accountable clinical reviewer.
Before supply runs out	Use the actual prescribed quantity and schedule to identify refill friction. Never infer permission to continue.	Reconciled current plan and an access resolution.
Any illness, procedure or lapse	Connect to clinician assessment and a documented return plan.	Treatment status clarified by the clinician.

Do not wait for day 7 to handle an urgent concern. Recent HF discharge follows the HF team's earlier timetable. The 2–4 week contact is a workflow checkpoint; extra renal testing is based on clinical need, not imposed on everyone. [14–16]

DIABETES AND COMBINATION REVIEW

REVIEW THE WHOLE REGIMEN WITHOUT SELLING THE NEXT COMBINATION

The T2D module exists only when the clinician selects it. It gathers the information needed for a decision on goals, response, tolerability and access. It does not score patients into a product or intensification pathway.

REVIEW AREA	USEFUL HCP SUPPORT	SERVICE BOUNDARY
Glucose and HbA1c	Capture the ordered result, actual use and barriers. ADA supports more frequent assessment after treatment change or unmet goals. [11]	No automated diagnosis, target or dose change; no mandatory daily glucose log for every patient.
Metformin and FDCs	Reconcile all ingredients, release form and renal/illness considerations using the exact PI. [7]	Never assume a plain-tablet cardiorenal indication transfers to an FDC.
DPP-4 and GLP-1 therapy	Give the clinician a complete list; ADA advises against concurrent DPP-4 and GLP-1-based therapy for extra glycaemic benefit. [8]	Flag for clinician review; do not discontinue or substitute.
Insulin or secretagogues	Make prior low-glucose episodes and the individual monitoring/rescue plan visible. [8,17]	Only the clinician changes insulin or secretagogue treatment.
Partial response	Distinguish missed use, supply, tolerance, changing illness and the selected clinical goal.	No promise that a higher strength or triple combination will solve it.
Missed doses	Check whether the clinic's product-specific written instructions are understood; route uncertainty.	No generic catch-up algorithm; no advice to restart an unresolved interrupted course.



The useful review output is a clinical decision: retain the plan, investigate, adjust, refer or arrange another review. The service records that decision. It must not interpret modest glucose change as proof that an HF/CKD purpose has failed.

The commercial asset is confidence in responsible review, not a conveyor belt to a bigger combination.

Combination review includes all prescribed, over-the-counter and relevant traditional remedies. The clinician decides what matters; the coordinator does not make interaction or eligibility judgements.

HF AND CKD MODULES

SEPARATE CARE NEEDS AND CONNECT THE HANDOVER

The shared service can support HF and CKD patients with or without diabetes when the actual Indian product label and clinician assessment permit. A single coordinating owner prevents duplicate prompts and conflicting advice.

MODULE	CLINIC-LED CONTENT	WHAT THE SERVICE MUST AVOID
HF follow-up	Named HF/physician team; discharge plan; clinician-selected symptom and weight information; fluid and diuretic context; follow-up appointment. [15,16]	No HF diagnosis, generic weight threshold, extra diuretic advice or universal “drink more water” message.
CKD follow-up	Arrange ordered renal function and albuminuria information; reconcile report dates and the clinician’s interpretation. [10,14]	No disease staging or automatic stop/continue instruction from an eGFR result.
Overlap and shared care	One current medicine list, each specialist’s tasks and an agreed person who communicates the final plan. [24]	No assumption that another clinic has reviewed a result merely because it received a copy.
Without diabetes	Explain the clinician’s HF/CKD purpose in neutral language and retain relevant safety counselling. [5,6,17]	No diabetes label attached to the patient; no default HbA1c programme solely because dapagliflozin was prescribed.

RENAL REVIEW NEEDS INTERPRETATION


KDIGO states that SGLT2 initiation alone does not require a change in routine CKD monitoring frequency and that an early reversible eGFR decrease is generally not a reason to discontinue. That is HCP context, not permission for staff to dismiss a result. Symptoms, volume status, other medicines and trajectory may require earlier assessment. [14]

RECENT HF DISCHARGE NEEDS ITS OWN TIMETABLE

The HF team specifies early review and monitoring. A routine two-to-four-week service contact must never delay that plan. Worsening symptoms or acute instability bypass routine reminders and enter the urgent-care route.

A molecule used across organs needs joined-up accountability, not one-size-fits-all monitoring.

SAFETY AND ESCALATION



MAKE URGENT CARE VISIBLE BEFORE THE FIRST CONCERN ARRIVES

These are examples for a medically approved routing protocol, not a diagnostic checklist. Staff record what the patient reports and escalate. They do not decide that a symptom is caused by dapagliflozin or that a negative checklist makes the patient safe.

REPORTED SIGNAL	REQUIRED ROUTE	COMMUNICATION RULE
Severe breathlessness, chest pain, collapse, confusion or inability to stay awake	Direct to immediate emergency care; notify the clinic without delaying care.	Never wait for an app reply or routine callback.
Vomiting, abdominal pain, unusual deep/rapid breathing or marked illness suggesting possible ketoacidosis	Immediate clinical/emergency assessment under the approved protocol. [17,18]	A normal or modest glucose value does not exclude ketoacidosis.
Severe genital/perineal pain, swelling or redness with fever or malaise	Immediate assessment; possible serious infection must not enter a routine reminder queue. [17]	Do not request intimate photos or offer an antifungal diagnosis.
Urinary symptoms with fever, flank pain or systemic illness	Urgent same-day clinical assessment; emergency care if severely unwell. [18,19]	Differentiate urgent routing from a claim that every urinary symptom is infection.
New genital irritation, discharge or recurrent discomfort without severe systemic features	Private prompt clinic contact for assessment and treatment decisions. [19]	No blame, retention pressure or “just tolerate it” reassurance.
Dizziness, poor intake, dehydration concern or low-glucose symptoms	Prompt assessment under the patient’s clinical plan; escalate severity. [8,18]	No universal fluid volume, insulin change or treatment decision.

The clinician provides product-specific safety and interruption instructions directly. The service ensures access to those instructions and urgent assessment; it never invents start/stop/restart advice. Critical concerns remain open until a documented handoff is achieved.

Local protocol must name operating hours, backup clinician, emergency fallback, acknowledgement target and escalation owner. A chat inbox is not an emergency service. Safety reporting also follows the PV pathway [22].

INTERRUPTION AND RE-ENTRY

A TEMPORARY INTERRUPTION NEEDS A CLINICAL RETURN PATH

Illness, fasting, procedures and hospital admission can change the treatment plan. Commercially, an interruption may become a silent long-term lapse. Clinically, an automatic restart can be unsafe. The service's role is to reconnect the patient to a responsible clinician.

TRIGGER	HCP REQUIREMENT	SERVICE ACTION
Planned surgery or prolonged fasting	The clinician sets an individual perioperative plan. ADA advises SGLT2 withholding for 3–4 days before elective surgery; the US dapagliflozin PI specifies at least 3 days if possible. [12,17]	Ask about upcoming procedures; arrange the clinician's instructions in advance. Do not generate medication dates.
Acute illness or reduced intake	Assessment and an individual illness plan, including whether interruption, testing or urgent treatment is needed. [14,18]	Route promptly. Record whether the clinical team reached the patient.
After hospital care	Reconcile the discharge prescription and the responsible outpatient team.	Retire obsolete reminders and prepare the next clinical review.
Restart or alternative plan	The clinician reviews recovery, intake and relevant risk factors and decides when or whether treatment resumes. [12,18]	Record the authorised disposition and next review; do not use an elapsed-day rule.
Lost follow-up	The clinic assesses current status and whether reassessment is needed before further use.	Use a consented re-entry invitation rather than a "resume your tablets" message.

NEUTRAL SERVICE LANGUAGE

“Your care plan needs review after your illness or procedure. Please contact the treating clinic using the agreed number. If you are severely unwell, seek urgent care now rather than waiting for a message response.”

Routine refill prompts must be suspended while treatment status is unresolved. Staff can change a communication status; only the clinician changes therapy. Preserve a clear audit trail of who issued each plan and when it superseded the earlier one.

The valuable continuity is continuity of clinical judgement. Uninterrupted dispensing is not the objective.





DOCTOR-FACING SUPPORT





MAKE THE REVIEW EASIER TO COMPLETE

After the clinician has selected dapagliflozin, the professional layer can carry the enabling brand and its approved product information. Its usefulness comes from reducing review effort while keeping decisions with the treating team.

HCP ASSET	CONTENT THAT EARNS USE	EVIDENCE OR CONTROL
Patient-fit and label check	Indication, exact product, renal limits and special-population exceptions for the clinician to assess.	Current Indian approval and PI; no automated eligibility. [5-7]
Counselling aid	Purpose, private genital/urinary concerns, volume context and how to contact the clinic.	Medical review with teach-back prompts. [18,19]
Review preparation sheet	Actual use, ordered results, unresolved concerns, concomitant medicines and access barriers.	One page; dated facts and source of information.
Illness and procedure aid	Space for the clinician's individual instructions and the responsible return-review contact.	Approved safety reference; no default patient regimen. [12]
HF/CKD handover sheet	Which team reviews symptoms, volume and renal results; next appointment and shared plan.	Guidance-aligned, indication-specific modules. [10,14-16]



WHAT THE DOCTOR RECEIVES

A concise queue of decisions that need attention: patient-reported issue, relevant facts, last instruction and the action awaiting the clinician. A resolved item records the decision and communication back to the patient. Repeated data entry, long symptom scores and unnecessary tests should be removed.

WHAT THE REPRESENTATIVE CAN DISCUSS

Clinic activation, workflow use and aggregate completion. Product claims remain approved and balanced. Representatives cannot access identifiable clinical queues, interpret results, decide whether a concern is serious or provide patient treatment advice.

If the support adds work without closing a decision, it has not earned the next call.

ACADEMY-BACKED EDUCATION

SIX MONTHS OF CASE LEARNING THAT CHANGES CLINIC PRACTICE




The Academy layer is an independent clinical education programme supporting the workflow. A recognised academic partner, faculty, governance and permissions must be secured before using its name. This note does not claim an existing endorsement, accreditation or CME credit.

MONTH	MINI-CME AND CASE SHARE	PRIMARY AUDIENCE	PRACTICE OUTPUT
1	Why the same molecule has different treatment purposes; label and patient-fit cases.	Diabetologists, endocrinologists, physicians.	Purpose and review-owner checklist.
2	Early dizziness, genital symptoms and urinary complaints without over-reassurance.	Physicians, diabetes teams; nurses in a separate skills session.	Private reporting and escalation routine.
3	Renal reports, early eGFR change and CKD care with or without diabetes.	Nephrologists and physicians.	Ordered-test to reviewed-plan handover.
4	HF across EF categories; discharge, volume and shared-care cases.	Cardiologists, HF teams and physicians.	Named post-discharge reviewer and patient plan.
5	Illness, fasting, procedures and safe clinician-led re-entry; combination risks.	All four specialty groups; endocrinologists.	Individual interruption and return-review aid.
6	Partial response, affordability, repeat prescriptions and missed follow-up.	Mixed-specialty faculty and clinic teams.	De-identified review of where continuity failed.

Suggested format: one 20-minute evidence session and one 15-minute case discussion each month, plus a short clinic aid. Months 1–3 support the 90-day pilot; months 4–6 continue only after the pilot gate. Faculty controls content and case interpretation. [8–19,24]

Use de-identified cases, balanced alternatives and documented conflicts of interest. Measure counselling competence, appropriate escalation and completed reviews. Attendance, certificates and product prescribing are not evidence that practice changed.

No patient identifiers, sales targets or brand-conversion contests in education. Sponsorship and professional interactions require current UCPMP review. [20] Local-language clinic training can support delivery without changing the scientific content.



LEADER STRATEGY

TURN PRESCRIPTION LEADERSHIP INTO CLINIC INFRASTRUCTURE`



A leader's exposure is familiarity without operational dependence. Competitors can reproduce a molecule reminder and undercut a price point. A reliable clinic routine creates a more demanding comparison, provided the clinic can retain control and patients retain choice.

LEADER MOVE	HOW IT WORKS	PROOF TO DEMAND
Defend existing default	Embed the common continuity spine in established high-value clinics.	Sustained clinic use and fewer unresolved due reviews.
Connect specialty relationships	Join diabetes, HF and CKD follow-up through one handover process where the clinic is capable.	Named ownership across transfers; no duplicate or conflicting prompts.
Protect first-pack confidence	Make private concerns and access problems easy to raise early.	Concern acknowledgement and documented clinical disposition.
Make fulfilment dependable	Use aggregate stock/access learning to improve supply and professional prescription reconciliation.	Fewer avoidable supply discrepancies, with patient choice preserved.
Scale only what survives	Train clinic backups and audit actual operation when the rep is absent.	Use continues without representative-led patient data entry.

WHERE THE LEADER SHOULD RESIST TEMPTATION

Do not make participation conditional on prescribing share, recruit patients before clinical selection or describe the service as exclusive access to care. A service that penalises switching undermines the trust it is intended to earn. Protect the default through performance and availability.


LEADER PILOT POSTURE

Start in 20–30 existing clinics across two dense clusters, with staged activation and a comparable set receiving usual support or later activation. Test whether the full core spine is usable before adding specialty modules. These numbers are illustrative planning choices, not a promised capacity.



Prescription leadership is a starting advantage. Make it visible in the clinic's ability to finish care.

Leader means leader in a defined, verified audit universe. The dated Forxiga disclosure is a public signal, not an assignment of the current leader for every market segment. [1]





CHALLENGER STRATEGY

CHANGE THE COMPARISON FROM RECALL TO COMPLETED CARE



Do not out-remind the leader. Give the clinic a reason to reconsider which team is most useful after the dapagliflozin decision. The strongest challenge is a measured improvement in one neglected task, delivered consistently enough to expand.

CHALLENGER MOVE	EXECUTION	COMPETITIVE TEST
Enter through a documented gap	Select clinics with missed early reviews, unclosed tolerability concerns or fragmented shared care.	The gap exists in baseline records, not only in rep opinion.
Lead with early confidence	Connect fit documentation, counselling and an accessible first review.	More due reviews end in an authorised plan.
Make specialty follow-up tangible	Support an existing HF or CKD pathway only where label and clinical ownership are clear.	The clinical handover improves without increasing unsafe advice.
Earn permission to discuss the brand	After molecule selection, show approved product information and aggregate workflow evidence.	Independent HCP consideration changes; no enrolment-for-prescription bargain.
Prove a repeatable advantage	Use phased activation or matched comparison and record resource use.	Improvement remains after initial launch attention fades.



Attack the unfinished clinic task. Make the leader defend an experience, not another slogan.

CHALLENGER PILOT POSTURE

Use 12–18 clinics in one accessible specialty corridor. Start with the core spine and one strong module, such as T2D with CKD review coordination. Pair on baseline volume, patient mix and due-review performance. Train the clinic team before the field team widens recruitment.

THE REASON A CLINICIAN MAY CHANGE PREFERENCE

A clinician can compare a repeated promotional claim with a service that prepares the relevant information, catches an unreported concern and closes a review. That experience may earn brand consideration. It does not justify a claim of superior efficacy, safer generic manufacture or guaranteed share transfer.





SELECTIVE SHARE AND MID TIER STRATEGY



CHOOSE ONE WEDGE WHERE CLOSURE CAN BE PROVED

A mid-tier brand does not need a national infrastructure promise. It needs one clinically defensible segment with enough density, a visible continuity gap and a clinic willing to own follow-up. Rank the choices by clinical readiness and operational tractability before commercial size.

RANK AND WEDGE	WHY IT IS ATTRACTIVE	ENTRY CONDITION OR LIMIT
1 T2D plus CKD follow-up	A concrete report-to-review task in established clinics; relevant to a broader treatment purpose.	Clinician selection, Indian-label fit, ordered tests and a named renal-review owner.
2 Newly initiated T2D	High visibility of first-pack access, purpose and early concerns; simpler pilot operations.	Existing diagnosis and prescription; no screening-to-product funnel.
3 Stable HF shared care	Clear need for specialty handover, including eligible patients without diabetes.	Experienced HF team and exact-product HF approval; do not use routine cadence for unstable patients.
4 Refill or substitution clusters	A measurable operational problem with potential supply and access remedies.	Document the gap; preserve affordability, choice and clinically authorised changes.
5 Recurrent genital-symptom dropout	A private, clinically meaningful problem where review may be missing.	Medical-led assessment and PV capacity. Never frame continued dapagliflozin use as the desired clinical outcome.

CKD without diabetes is also a defensible subsegment where the actual product's approved CKD indication, specialist assessment and follow-up capacity support it. It should not become a broad public "kidney protection" recruitment campaign. [5,14,27]

RECOMMENDED STARTING WEDGE

Choose T2D plus CKD review continuity when the clinic already has a dependable renal-review pathway. Otherwise start with newly initiated T2D. Use 6–10 clinics in one geography; prove the task and unit economics before widening the programme.

> *A narrow workflow completed reliably is a stronger position than a national promise the team cannot staff.*

The ranking is a strategic judgement, not a measured national market ranking. Replace it where baseline clinic evidence or the selected brand's approved indications point elsewhere.



FIELD FORCE STORYLINE

REPLACE THE REMINDER CALL WITH A USEFUL CLINIC DECISION



The field force opens the professional conversation and supports clinic activation. It does not enrol patients into treatment, run clinical triage or access identifiable patient data.

OLD CALL	NEW CALL
Repeat the molecule's benefits	Ask which post-prescription task most often fails to reach review.
Present every asset	Use one relevant workflow aid and agree the next clinic action.
Ask for more prescriptions	Ask whether the clinic will test a defined continuity task after clinical selection.
Count programme registrations	Review aggregate due-review closure, burden and access resolution.
Treat objections as resistance	Separate clinical concerns, affordability, service burden and supply problems.

THIRTY-SECOND STORYLINE

"Once you have selected dapagliflozin, the plan can still break at the first pack, an early concern or the next review. This clinic-branded pathway helps your team connect those steps. Patients receive neutral support and all treatment decisions return to you. The test is whether more due reviews end in a documented plan."

THE FIVE-MINUTE STORYLINE

TIME	REP ACTION
Minute 1	Establish one actual clinic gap without requesting patient identities.
Minute 2	Show the purpose-concern-review-refill pathway and the relevant module.
Minute 3	Demonstrate the one-page review queue, neutral patient material and safety boundary.
Minute 4	Explain the aggregate primary metric, staff effort and response ownership.
Minute 5	Agree the clinic lead, readiness check and activation decision; discuss the brand only within approved HCP communication after molecule selection.

One clinic problem. One usable aid. One accountable next step.

ASSET SYSTEM

KEEP THE OPERATING KIT SMALL ENOUGH TO USE

Low friction is a competitive requirement. The clinic should not have to reconcile several portals, multiple campaign identities or conflicting patient messages to run one continuity pathway.

CORE ASSET	USER AND PURPOSE	RELEASE RULE
Clinical enrolment and review card	Clinician/coordinator: purpose, module, consent, contact, due date and owner.	No automated treatment selection or score.
Neutral care guide	Patient: clinic-approved purpose, contact routes, privacy and urgent-care information.	Clinic identity; no product brand, comparative claims or sales links.
Private concern contact	Patient/coordinator: a discreet way to request clinical attention.	No intimate photos; no rep access.
One-page review queue	Clinician: relevant facts and outstanding decisions.	Separate facts, patient reports and clinician instructions.
Illness and procedure handover	Clinician: individual plan and review ownership.	No system-generated interruption or restart instruction.
Refill discrepancy workflow	Clinic: current prescription versus reported supply; stock and affordability friction.	Patient messages say “prescribed medicine”; brand reconciliation stays in professional records.
Six mini-CME case packs	Faculty/HCPs: the six-month practice sequence.	Independent content, consented cases and no product-conversion objective.
Aggregate dashboard and rep aid	Leadership/field: adoption, closure, burden and defined-market signals.	No identifiable symptoms, lab results or patient histories.

Use a consented local-language channel, a short teach-back and an accessible alternative for patients who cannot use digital tools. Translate and clinically review essential safety language before release. Do not use engagement streaks, disease labels on shared-device notifications or repeated promotional messages.

If an asset does not help the patient reach the clinic or help the clinic close a task, remove it.

No platform lock-in is needed to test the model. Retain exportable clinic records, role-based permissions and a safe service-exit process.

MEASUREMENT MODEL

MAKE COMPLETED REVIEW THE PRIMARY DECISION METRIC

The primary decision metric is the improvement in on-time reviewed-plan completion versus a pre-specified comparison. Commercial movement is measured downstream and separately; the service must first demonstrate that it reliably completes a clinically useful task.

STAGE	MEASURE	DENOMINATOR AND INTERPRETATION
Clinic activation	Clinics actively operating the workflow.	Ready clinics trained and live; report weekly use and staff time.
Appropriate use and adherence	Documented clinician fit and teach-back; reported missed use and reasons.	All enrolled patients for process; respondents for reported use. Show non-response separately; self-report is not verified adherence.
Safety and review capture	Concerns acknowledged, clinically handed off and resolved; due reviews completed.	All reported concerns and all mature due-review records, shown separately.
PRIMARY Reviewed-plan completion	Patients with the first planned review completed within its prospectively recorded window and a clinician disposition.	All enrolled patients whose first review window has closed. Missing status counts as not completed.
Exact-brand continuity	Concordance between current authorised prescription and observed dispensing.	Separately consented/authorised professional audit. Report unknown supply and authorised changes separately.
Commercial movement	Defined-market prescription/dispensing share or standardised units, versus comparison.	Same formulation, geography, channel and period. No inference from registrations alone.

Freeze each review date and tolerance window at enrolment. A clinician may amend it for clinical reasons with a timestamp, never retrospectively to improve the metric. Count each patient once for the primary first-review measure; report later reviews separately. A documented clinically appropriate stop or switch counts as a completed review.

Show numerator, denominator, percentage-point difference, missingness and clinic-level variation. Stratify T2D, HF and CKD without double-counting people with overlap. Report deaths, transfers and withdrawals transparently; pre-specify handling and a sensitivity analysis rather than silently deleting them.

An example of +15 percentage points means 65% versus 50%, not 15% relative growth. It is an illustrative management threshold for testing, not a predicted effect.

COMMERCIAL PROOF AND ECONOMICS

A USEFUL SERVICE STILL HAS TO EARN ITS COST



The causal chain is clinic activation → better continuity and review → greater professional trust → an opportunity for authorised prescription fulfilment and brand preference. Each link needs evidence. Neither a clinical trial of dapagliflozin nor a service registration count proves commercial return.

QUESTION	REQUIRED EVIDENCE	AVOID THE FALSE CONCLUSION
Did the workflow improve?	Pre-specified baseline and concurrent matched or phased comparison, with mature cohorts.	A before/after rise alone may reflect seasonality or launch attention.
Did continuity change?	Documented authorised treatment status, access resolution and separate supply audit.	A medically appropriate switch is not preventable leakage.
Did commercial movement follow?	Independent aggregate data with consistent product, channel and geographic definitions.	Increased stockist purchases are not confirmed patient use.
Was it economical?	Full service cost, staff time and conservative attributable contribution.	Sales revenue is not margin; existing packs are not incremental packs.
Can it scale?	Stable clinic usage, staffed response capacity and repeatable training.	A rep-maintained demonstration is not an adopted clinic routine.



Use transparent unit economics

Cost per additional completed review = incremental programme cost ÷ additional reviews versus comparison. If the estimated improvement is zero or negative, do not manufacture a positive efficiency ratio. Include clinical oversight, coordinator time, training, technology, PV, quality review and field support.

Commercial break-even incremental packs = incremental programme cost ÷ net contribution per incremental pack. Use net realised contribution after relevant discounts and variable costs. Test low, base and high attribution assumptions; do not count every retained pack as caused by the service.

A 90-day pilot can test adoption and continuity. It cannot establish a reduction in mortality, kidney failure or hospitalisation.

GOVERNANCE AND GUARDRAILS

KEEP THE PATIENT SERVICE NEUTRAL AND THE CLINICAL AUTHORITY CLEAR

Governance is part of the operating design. The sponsor may enable the service; the clinic controls treatment and access to identifiable clinical information. Separate clinical care, safety reporting and commercial analytics from the outset.

CONTROL	REQUIRED DESIGN
Patient-facing neutrality	Clinic identity and brand-neutral language. No product recommendation, dose choice, start/stop/switch/restart advice, diagnosis or automated clinical decision.
Professional brand layer	Approved, balanced brand communication only after clinician molecule selection. No prescribing quota or benefit linked to brand choice. Review current UCPMP requirements. [20]
Safety ownership	Named clinic lead and backup, tested urgent routes, unresolved-concern queue and documented handoff. No incentive to minimise adverse-event counts.
Pharmacovigilance	Separate trained PV route for suspected events, special situations and complaints as required; timestamps, follow-up and reconciliation under approved SOPs. Do not wait for causality to be proved. [22]
Consent and minimisation	Explain purpose, channels, authorised caregivers, optional participation, withdrawal and data uses. Collect only what supports the chosen pathway. [21]
Access and separation	Clinic clinical records and necessary PV records have restricted roles. Sponsor/rep dashboards use aggregates with small-cell suppression and no patient identities or symptom histories.
Version and label control	Current Indian PI, medical/legal approval, language review, change log and withdrawal of superseded content.
Continuity on exit	Keep access to treating care and provide a clear handover if sponsorship, vendor service or patient participation ends.

The DPDP Rules 2025 include phased enforcement. Legal review must confirm which provisions apply at launch and address other applicable obligations. This design is not a certification of compliance. A withdrawal from optional support must not be represented as withdrawal from clinical care.

No commercial result compensates for an unsafe route, an unauthorised treatment instruction or misuse of patient data.

FIRST-MOVER PILOT



CONFIGURE ACTIVATE AND PROVE WITHIN NINETY DAYS

The first wave should be small enough to operate safely and large enough to expose routine failure. Complete the readiness work before enrolment. The six-month education architecture continues beyond day 90 only if the decision gates support it.

PERIOD	OPERATING PRIORITY	EXIT EVIDENCE
Days 1–15 Configure	Choose posture and cohort; inspect baseline gaps; verify labels; name clinical/PV/data owners; approve scripts, consent and comparison.	Tested urgent route, trained backup and frozen metric definitions.
Days 16–30 Activate	Start a staggered clinic wave; confirm first-pack access and patient understanding; inspect staff workload.	Actual clinic use, visible due dates and no unresolved critical service defect.
Days 31–60 Operate	Run early checks and reviews; audit handoffs, missing status, access friction and staff effort weekly.	Mature first-review cohorts and documented clinical dispositions.
Days 61–90 Prove	Complete cohort follow-up; compare results; assess aggregate commercial movement and cost; decide next wave.	Decision report with denominators, limitations and a funded capacity plan.

POSTURE	ILLUSTRATIVE PILOT SHAPE	MAIN TEST
Leader	20–30 existing clinics in two clusters.	Can the core pathway remain dependable at breadth?
Challenger	12–18 clinics in one specialty corridor with matched or phased comparison.	Does closing a neglected task change the professional comparison?
Selective share	6–10 clinics in one wedge and geography.	Can dense execution produce repeatable value at affordable cost?

Set an enrolment cutoff that allows the primary review window to mature by day 90. Later enrolments must not inflate the completion rate. Patients needing longer clinical follow-up retain their care plan after the commercial test closes.

Clinic counts and timelines are illustrative. Patient targets follow staffed capacity, expected eligible flow and a justified evaluation design; no sample-size or statistical-power claim is made.





GO OR NO GO

ALLOCATE CAPACITY TO CLINICS THAT CAN CARRY THE PROMISE



Freeze the decision rules before the first enrolment. The numerical examples below are management assumptions to calibrate to baseline and cohort size. Label compliance, clinical ownership and a functioning urgent route are mandatory.

GATE	ILLUSTRATIVE PASS RULE	IF IT FAILS
Readiness	Every active clinic has signed clinical ownership, current PI mapping, trained backup, consent/PV process and passed route tests.	Do not enrol until corrected.
Primary result	At least +15 percentage points in on-time reviewed-plan completion versus the pre-specified comparison.	Investigate imbalance, missingness and execution; extend or redesign the test.
Absolute performance	Aim for ⩾80% completion and ⩾70% of activated clinics using the workflow weekly in the final month.	Reduce burden or cohort size before expansion.
Service safety	Every urgent signal has a documented handoff audit; no unresolved critical routing failure.	Pause affected enrolment and investigate. This is not a zero-adverse-event target.
Commercial plausibility	A credible directional signal in the defined audit universe, with acceptable economics under conservative assumptions.	Withhold share-gain and return claims; reconsider the commercial model.
Capacity	The next wave has funded clinical oversight, coordinator time, PV coverage, training and supply support.	Hold expansion while preserving existing patients' care.

LEGITIMATE FIRST-MOVER URGENCY

The same molecule-wide opportunity is being shown to direct competitors. Earlier adoption can create clinic familiarity, operating knowledge and a credible body of service evidence. Those advantages must be earned; the note claims no artificial deadline, exclusive territory or reserved number of slots.

Allocate actual implementation capacity by readiness, clinic density and evidence of a meaningful gap. Publish real staffing limits and activation dates before committing. Competitor cohorts must never share confidential plans or identifiable patient data.

Move early enough to learn first. Expand only when the clinic can keep the promise.

LEADERSHIP DECISION



DEFEND ATTACK OR CAPTURE THE NEXT COMPLETED CARE PLAN

Dapagliflozin's competitors can all repeat a familiar molecule story. The harder position to displace is the team that helps a clinic explain the selected purpose, surface a concern, complete a review and reconcile the next step.

CHOOSE	COMMIT	DEMAND THE PROOF
DEFEND Market leader	Make cardio-renal-metabolic continuity part of the existing clinic relationship.	Sustained adoption, dependable handover and protected professional preference.
ATTACK Challenger	Make early safety confidence and completed follow-up the basis of comparison.	A measured improvement in the clinic task and a separately verified commercial signal.
CAPTURE Selective-share brand	Choose one documented leakage point in a dense, clinically ready segment.	Repeatable closure and viable economics before broadening the footprint.

THE DECISION TO TAKE NOW

Name the competitive posture, the first clinic cohort, the clinical owner and the primary review-completion metric. Commit the resources for a 90-day test. Require the safety gates, a credible comparison and a conservative commercial readout before scale.

The recommended default is one common continuity spine with clinician-selected modules. Start where the clinic already has the strongest review ownership. Add complexity only when it closes a documented gap. A brand earns the right to scale through service performance, not the breadth of its launch promise.

This opportunity exists across dapagliflozin. Decide which workflow to make dependable before a competitor makes it the clinic's expectation.

The patient receives neutral clinic support. The clinician retains judgement. The brand competes on the usefulness of the system it enables.

Decision note for competing Indian dapagliflozin leadership teams. No current brand has been assigned an unverified national rank; no service effect, Academy endorsement or commercial return is represented as already achieved.







Indian market and approval evidence

[1] AstraZeneca Pharma India. Annual Report 2024–25. Printed pages 51 and 71.
Company-reported 350+ generic brands including combinations, IQVIA MAT December 2024; separate 120+ monotherapy and Forxiga value-leadership statements. Dated public proxies, not a current independently audited leaderboard.

[2] NPPA. Retail price computation for dapagliflozin 10 mg. May 2025 data; file I/12896/2026, final four PDF pages.
Original worksheet downloaded and inspected. INR4,177,480,046 MAT equals INR417.75 crore. AstraZeneca, Sun and Abbott Healthcare are excluded from price fixation and their sales cells are blank. Use only as a partial-universe value proxy; 148 rows are packs, not 148 distinct brands.

[3] Eris Lifesciences. Annual Report 2024–25. Printed page 34, Diabetes Care.
Primary company report hosted in an exchange-filing archive. Gluxit fourth-among-generics statement appears in the FY25/AWACS MAT March 2025 context. No current complete-molecule ranking inferred.

[4] Gopal A et al. Prescription Patterns of Sodium-Glucose Co-Transporter 2 Inhibitors among Nephrologists. Indian Journal of Nephrology. 2026;36(5):596–600.
2024 single-centre Kochi cohort: 399 eligible, 81 SGLT2 users and 79 dapagliflozin users. Table 1 supports the counts. Cohort selection and local practice preclude national prevalence or specialty-share inference.

[5] AstraZeneca India. Dapagliflozin receives additional CKD indication approval. 29 November 2022.
Primary Indian approval disclosure: CKD with/without diabetes and initiation threshold of eGFR ≥25 in the described approval. A dated disclosure does not replace the current approved PI for each brand.

[6] AstraZeneca India. Dapagliflozin gets extended adult HF indication approval. 25 July 2023.
Primary disclosure of Indian HF expansion across ejection fractions. Promotional comparative language in the release is not adopted as a universal superiority claim.

Product and diabetes sources

[7] Torrent Pharmaceuticals. STALIX DM prescribing information. Dapagliflozin sitagliptin and metformin extended-release tablets.
Section 4.1 specifies adult T2D. Component discussions elsewhere do not extend the combination's indication automatically. Medical review must reconcile the latest approved combination-specific permission and PI.

[8] American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment. Standards of Care in Diabetes 2026, section 9.
Comorbidity-directed treatment and combination review; recommendation 9.18 addresses DPP-4 plus GLP-1–based therapy. Guidance supports clinician decisions, not patient automation.

[9] American Diabetes Association. Cardiovascular Disease and Risk Management. Standards of Care in Diabetes 2026, section 10.
Outcome-directed treatment in appropriate T2D populations and HF evidence. Benefits must remain population- and endpoint-specific.

[10] American Diabetes Association. Chronic Kidney Disease and Risk Management. Standards of Care in Diabetes 2026, section 11.
Kidney assessment, renal/albuminuria monitoring and clinician-led treatment context. Not authority for a universal service testing schedule or an Indian brand label.

[11] American Diabetes Association. Glycemic Goals Hypoglycemia and Hyperglycemic Crises. Standards of Care in Diabetes 2026, section 6.
Recommendation 6.2: at least twice-yearly glycaemic assessment, more often such as every three months after changes or when goals are unmet. Monitoring remains individualised.

[12] American Diabetes Association. Diabetes Care in the Hospital. Standards of Care in Diabetes 2026, section 16.
Perioperative SGLT2 withholding and clinical reassessment before resumption. This is HCP source context; the service does not issue interruption or restart instructions.

Cardiorenal guidance and safety

[13] Davies MJ et al. Management of type 2 diabetes 2026. ADA and EASD consensus report. Published 2 October 2026.
Current consensus extends the focus beyond hyperglycaemia toward whole-person and organ outcomes. Individualisation and local regulatory constraints remain essential.

[14] KDIGO. Clinical Practice Guideline for Evaluation and Management of Chronic Kidney Disease. 2024.
Recommendations and practice points 3.7: SGLT2 eligibility context, illness/fasting cautions, monitoring and initial eGFR change. Guideline thresholds do not override an Indian product label.

[15] McDonagh TA et al. 2023 Focused Update of the 2021 ESC heart-failure guidelines. European Heart Journal. 44:3627–3639.
HF recommendations across EF categories and close follow-up after acute HF. Supports a separate HF module and early clinical ownership, not a generic two-to-four-week delay.

[16] AHA ACC and HFSA. 2022 Guideline for the Management of Heart Failure. Official summary.
SGLT2 inhibitors form part of the HFrEF multidrug framework. Dapagliflozin does not replace the rest of clinician-directed HF management.

[17] US Food and Drug Administration. FARXIGA prescribing information. Revised June 2026.
Updated genitourinary safety, ketoacidosis/volume precautions, perioperative and missed-dose information. US label used as a safety reference, not Indian authorisation; patient-specific instructions remain clinician-issued.

[18] AstraZeneca UK. Forxiga 10 mg Summary of Product Characteristics. Current public version checked 17 October 2026.
Renal/glucose distinction, volume, infection, acute-illness and safety context. UK authorisation must not be substituted for an Indian brand's approved PI.

Implementation and governance sources

[19] UK Kidney Association. SGLT2 inhibition in adults with kidney disease 2023 update. BMC Nephrology. 24:310.
Final society guideline on implementation, genital hygiene, symptom counselling, urinary infections and appropriate clinical review. It does not validate the proposed service.

[20] Department of Pharmaceuticals. Uniform Code for Pharmaceutical Marketing Practices 2024. Official guidelines portal.
Use the current code and amendments for claims, professional interactions, education and sponsorship. This note is not a legal compliance opinion.

[21] MeitY. Digital Personal Data Protection Rules 2025 and enforcement materials.
Official Rules and phased enforcement context. Legal review must confirm launch-date applicability. Consent, access control and minimisation are required design choices here.

[22] Indian Pharmacopoeia Commission. Pharmacovigilance Programme of India adverse-reaction reporting resources.
Official HCP and patient reporting resources. Organised-support-program collection, company timelines, special situations and safety agreements need an approved PV procedure.

[23] KDIGO. CKD Evaluation and Management guideline hub. Status checked 17 October 2026.
The 2024 guideline is published; the 2027 focused update is under public review through 4 November 2026. Draft recommendations are not treated as final guidance in this playbook.

[24] AHA ACC ADA and ASN. 2026 Guideline on Cardiovascular-Kidney-Metabolic Syndrome. Official guideline hub.
Supports coordinated attention to overlapping cardiovascular, kidney and metabolic needs. The proposed service does not perform CKM staging, risk scoring or diagnosis.

STRATEGIC OPPORTUNITY & CTA

The decision for a dapagliflozin brand team is simple: Will you remain another brand competing on molecule recall and cardiorenal benefit claims, or become the brand that helps clinics turn every appropriate prescription into a completed, reviewed, and clinically managed care plan?

Dapagliflozin doesn't need another glucose-reminder campaign. It needs a brand that owns the prescription-to-reviewed-plan connection - helping clinics preserve the purpose of treatment, surface early concerns, coordinate diabetes, heart failure and kidney-care follow-up, and ensure every next step has a clear clinical owner.

Old rule: Win the prescription.
New rule: Own the handover to the next clinical decision.

EMAIL:
Amit@inditech.co.in

WEBSITE:
Www.inditech.co.in

The next winning dapagliflozin brand will become the clinic's cardiorenal-metabolic continuity partner - connecting the first pack, patient-reported concerns, indication-specific review, and clinician-led decisions when treatment needs to change or resume after an interruption.

The opportunity is to make completed clinical reviews a reason for HCP preference - building a clinic routine competitors cannot replicate with another product claim alone.

Next Steps

If you would like to explore how these ideas can be adapted to your brand strategy, we would be happy to discuss them further.

Get in touch with our team to schedule a 30-minute Dapagliflozin Continuity Diagnostic and identify your brand's competitive posture, highest-value clinic workflow gap, priority specialty or clinic cluster, and a focused 90-day pilot.





INDITECH HEALTH SOLUTIONS

PUBLICATION NO. 2026 10 114